Launch a new category in skin nutrition in your market.
en-CLEAR is a gut-skin axis formulation designed by the ENBIOSIS Digital Twin and AI engine. The same engine sits behind en-TEAR. We appoint one exclusive partner per territory.
- Gold, UK Tech Rocketship Awards 2022
- AI-designed formulation
- Food-grade ingredients
- 90-day programme
One formulation, built into your daily routine.
Designed to fit into an existing daily routine: a 90-day programme in three 600 g jars.
43 million people live with psoriasis. Almost everything they are offered works on the skin.
Physician-diagnosed cases alone reach 43 million worldwide, and self-reported figures run past 100 million (Global Psoriasis Atlas). Creams, light therapy and systemic drugs all work from the outside in.
Research is moving inward. Studies have identified a distinct gut microbiome signature in people with inflammatory skin conditions: fewer short-chain-fatty-acid producers, a weaker gut barrier, and immune signals that travel to the skin. This is the gut-skin axis.
en-CLEAR is built for that shift.
A daily food supplement, three 600 g jars, 90 days, designed around the gut-skin axis from the first line of the formula.
Most supplements start with an ingredient. en-CLEAR starts with a target.
The usual way to build a supplement is to take a known ingredient and look for an effect. The ENBIOSIS engine works in reverse. It models what the gut microbiome needs to produce, then designs the food-grade inputs that get it there.
- 01
Simulate
A digital twin of the gut microbiome models how microbial communities process food-grade inputs and which metabolites they produce.
- 02
Select
AI picks the precursors predicted to lead to the target metabolites.
- 03
Formulate
The result is one ready-to-use daily product.
The formula is not a list of familiar ingredients. It is the output of a model.
The engine behind en-CLEAR has already delivered clinical results.
en-TEAR, the engine's first formulation
In a pilot study, tear production rose 60.7% after 8 weeks (Schirmer test, +6.03 mm), and the improvement held at 16 weeks, after intake had stopped. en-TEAR is now in a placebo-controlled randomised trial with a planned 130 participants (NCT07453212).
Pilot: single-arm, n=20 (NCT07148271). Results not yet peer-reviewed.
The ENBIOSIS algorithm, 12 months on
In a multicentre randomised trial in irritable bowel syndrome, 62.5% of participants on the ENBIOSIS microbiome-guided diet were responders at 12 months, against 34.5% on low-FODMAP (Gut Microbes, 2026).
Five placebo-controlled trials running now
Registered on ClinicalTrials.gov, with results to be posted there.
en-CLEAR's own study
A clinical study of en-CLEAR is in preparation. Once it is registered, the registry number and the centres appear here.
We publish as we go. Our early user programme starts with the Türkiye launch. Partners receive its reports as the data comes in.
See the full evidenceOne market. One partner.
Exclusive distribution
- You
- Register and sell en-CLEAR across your territory.
- We
- Finished product, full territory exclusivity.
Agency
- You
- Open doors to pharmacy chains, clinics and retailers.
- We
- Supply and invoice direct, you earn commission.
Premix
- You
- Produce under your own brand.
- We
- Bulk formulation for your lines.
Licensing
- You
- Build the formula into your own products.
- We
- License, active blend, technical transfer.
What you get
Your territory, exclusively
No second partner in your market.
Margin that works
Distributor pricing set for your channel, with volume tiers agreed before launch.
Launch support
Registration dossier, label draft and launch plan for your market.
A complete marketing kit
Imagery, education materials, sales deck.
Direct access to our science team
For your key accounts and medical advisors.
The whole portfolio
en-TEAR, en-JOY&FIT and en-MASCULINE through the same relationship.
From first call to first shipment.
- 1
30-minute call
Your market, your channels, our terms.
- 2
Territory reserved
We hold your market while we agree terms, and share the distributor pack under NDA.
- 3
Registration
We prepare the dossier; you file it in your market.
- 4
First shipment
Territories are allocated in the order partners qualify.
Open now
Europe, the United Kingdom, the Gulf, Central Asia and North Africa.
Already allocated
Türkiye, direct to consumer.
Your market is not on the list? Ask. We are opening new territories every quarter. Get in touch
Start with en-CLEAR. Grow with the portfolio.
- en-TEARGut-eyeOn sale in Türkiye. Pilot results in, placebo-controlled RCT under way.
- en-JOY&FITGut-metabolicComing next. Open for licensing.
- en-MASCULINEGut-hormoneComing next. Open for licensing.
The team that builds nutraceuticals the way pharma builds drugs: target first, clinical trials on the public record.
Founded by Ömer Özkan (CEO), Prof. Özkan Ufuk Nalbantoğlu (CTO) and Aycan Gündoğdu (Chief Science Officer). In operation since 2019, built on microbiome and AI research that predates the company.
- registered clinical studies
- Nine
- peer-reviewed papers
- Six
- UK Tech Rocketship Awards 2022
- Gold
- countries using the platform
- 16+
Your market could be next.
Tell us where you sell. We reply within two business days and tell you if your territory is open.